Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized observer-blind study of mRNA-1083 in adults ≥50 years
jRCT2031240429Phase 3Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, single-blind trial of mCOMBRIAX in coronavirus disease 2019 (COVID-19) and influenza, sponsored by Moderna Inc. Primary endpoints: Geometric mean level of antibodies for influenza at Day 29, Geometric mean level of antibodies for SARS-CoV-2 at Day 29 and 6 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
mCOMBRIAX
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on jRCT2031240429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240429.